Assembly for an injection device and injection device
The injection device assembly with a telescopic needle cover and coupling element adjusts needle insertion depth to 2-7 mm, addressing the issue of fixed depth in autoinjectors for children and thin-skinned adults, ensuring safe drug delivery.
Patent Information
- Application Number
- JP2024535739
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-15
- Filing Date
- 2022-12-13
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing autoinjectors are not suitable for children and adults with low BMI due to the fixed needle insertion depth, which is not adaptable to thinner skin conditions.
An assembly for an injection device that includes a housing with a telescopic needle cover and a coupling element, allowing the needle to be inserted to a variable depth by displacing the medicament container proximally, thereby controlling the insertion depth to 2-7 mm, preferably 3-5 mm, suitable for children and thin-skinned adults.
Enables the use of standardized needle lengths for children and adults with thin skin, preventing intramuscular injection and ensuring safe and effective drug delivery.
Smart Images

Figure 2024544286000001_ABST
Abstract
Description
[Background technology]
[0001] Various autoinjectors for use in adults are known. They are equipped with a needle configured to be inserted into the patient's body to a certain injection depth before releasing the pharmaceutical agent. In many cases, this specific injection depth is not suitable for use in children and / or adults with certain conditions of thinning of the skin, such as low BMI. For example, children have thinner skin than adults, and the underlying tissue also has a smaller thickness when compared to adults. Therefore, a reduction in the injection depth is desirable. Summary of the Invention [Problem to be solved by the invention]
[0002] It is an object of the present disclosure to provide an improved assembly for an injection device, such as an autoinjector, particularly with respect to reducing needle insertion depth. [Means for solving the problem]
[0003] This object is achieved by the subject matter of the independent claims. Advantageous embodiments and refinements are the subject matter of the dependent claims and the description.
[0004] In the present disclosure, an assembly for an injection device, for example an automatic injection device, is proposed. The assembly includes a housing, the housing includes a first support surface (or support support surface) configured to support the medicine container in a distal direction. The assembly further includes a needle cover, for example on a distal end of the needle cover, configured to protrude from the housing further than the needle of the medicine container in at least a first state and in a first position, the needle cover being arranged in the housing to telescopically move within the housing when a force is applied in a proximal direction. The needle cover includes an opening through which the needle passes when the needle cover is moved to a second position within the housing. The assembly also includes a coupling element configured to, for example, push the medicine container to move the medicine container in a proximal direction in parallel, for example coupled, in tandem and / or together with the needle cover when the needle cover is moved in a proximal direction beyond the second position. During use of the injection device, the coupling element is configured to axially displace the medicine container in a proximal direction from the first support surface. Movement of the medicament container in the proximal direction may increase the distance of the medicament container to the first support surface in the proximal direction. During use of the injection device, the coupling element may be configured to axially displace the medicament container in the proximal direction from the first support surface, e.g., thereby preventing insertion of the needle into the patient's body beyond a predetermined injection depth, e.g., the injection depth is in the range of 2 mm to 7 mm, preferably in the range of 3 mm to 5 mm. The device may prevent intramuscular injections for children or patients with thin skin.
[0005] The coupling element and the medication container may be configured to move together, for example axially away from and / or towards the first bearing surface.
[0006] The injection device may be a device for injecting a medicine into a patient's body. Preferably, the injection device is a pen-type device. The automatic injector may be configured to provide a single shot of medicine before being discarded. Preferably, the automatic injector is configured to essentially empty the medicine container in a single shot. The automatic injector may include an energy store, e.g., a drive spring, for expelling the medicine from the medicine container, e.g., energy of the energy store may be released during a single actuation / shot.
[0007] The assembly may include a pharmaceutical container. The pharmaceutical container may include a pharmaceutical container body and a needle protruding from a distal end of the pharmaceutical container body. The needle may be fluidly connected or connectable to an interior of the pharmaceutical container body. The needle may be fixed to the pharmaceutical container body. The pharmaceutical container may be a syringe-type pharmaceutical container. The pharmaceutical container body may include a tubular, e.g., cylindrical, shape. The interior of the pharmaceutical container body may include a tubular, e.g., cylindrical, shape. The pharmaceutical container may include a stopper configured to move within the pharmaceutical container to reduce a size of the sealed compartment and to expel the pharmaceutical from the interior of the pharmaceutical container, e.g., through the needle. The stopper may proximally seal the interior of the container body. The pharmaceutical container may be a syringe with a staked needle.
[0008] The first support surface may limit the axial movement of the container in the distal direction. Proximal movement may be permitted, for example in a limited manner. The first support surface may be partially, mainly or entirely directed in the proximal direction. The first support surface may be provided directly on the housing or on an additional part that is fixed at least in the distal or proximal direction relative to the housing. The container may include a support surface that faces or mainly faces the first support surface and is configured to contact the first support surface. The support surface of the container may be arranged on the container body, for example on a shoulder of the container, for example in the area where the needle is fixed to the container housing, or on a radial flange of the container body arranged at the proximal end of the container body, for example opposite the needle. Alternatively, the container may include an adapter portion that accommodates the container body and provides a support surface for the container, for example when a container body with a small diameter is used.
[0009] The needle cover may be configured to at least radially cover a portion of the needle protruding from the housing in at least the first condition. A force driving the needle cover proximally into the housing may be generated by pressing the second support surface against the patient's skin.
[0010] The coupling element may be rigid and / or non-deformable, for example when subjected to an axial force. Alternatively, the distance element may be at least partially made of a compressible and / or soft material, for example to reduce impact forces on the patient's skin. The compressibility of the distance element, as referred to herein, may cause the distance element to be compressed such that after fully inserting the needle into the distance element and activating the ejection of the medicament by the drive mechanism, the impact force of the drive mechanism causes the needle to be further inserted into the patient's body to reach a predetermined injection depth.
[0011] The proposed assembly makes it possible to use medicine containers with standardized needle lengths also for children.
[0012] According to a further embodiment, the coupling element may be disposed on the first support surface and configured to be disposed between the first support surface and the medication container, the coupling element including a distal extension configured to extend along a needle of the medication container, and the needle cover may cover at least a portion of the distal extension protruding radially from the housing, at least in the first state.
[0013] Alternatively, the coupling element may be configured to be disposed on the needle of the medication container, or on the neck of the medication container body to which the needle is secured.
[0014] Additionally, the coupling element may include a third bearing surface disposed on a distal end of the coupling element, for example, on the distal end of the distal extension. The third bearing surface may be at least 3 mm 2 , e.g. at least 5 mm 2 , e.g. at least 10 mm 2 For example, the third support surface may have a ring shape with a diameter of 8.5 mm or more and a width of 0.5 mm or more, resulting in a surface area of 14 mm 2 The third support surface may have an area of at least 1.0 mm. The third support surface and the opening may be dimensioned such that the third support surface may be disposed within the opening. The opening may be disposed in the second support surface. The third support surface may be at a first location of the needle cover and may be disposed within the needle cover. The third support surface may be axially aligned with the second support surface at least at a second location of the needle cover.
[0015] Also, the third support surface can be configured to be inserted into the opening in the needle cover when the needle cover is moved to the second position and to contact the patient's skin when the needle cover reaches the second position. The opening can be configured to allow the distal extension to pass when the needle cover is moved sufficiently deep into the housing, e.g., such that the distal extension can contact the patient's skin together with the second support surface, e.g.
[0016] Alternatively, the third support surface may be configured to contact, e.g., abut, the needle cover, e.g., an inner support surface surrounding the opening of the needle cover, when the needle cover reaches the second position. In such a case, the predetermined injection depth may be defined by the difference in offset from the needle tip and the third support surface, and the thickness of the needle cover between the second support surface and the inner support surface of the needle cover.
[0017] According to further embodiments, the distal extension is formed as a hollow cylinder configured to surround at least a portion of the needle. According to other embodiments, the distal extension has a cross-sectional configuration that is polygonal or elliptical.
[0018] Preferably, the third support surface is configured to be axially, e.g. proximally, e.g. along a major axis, e.g. completely and / or evenly offset from the needle tip of the needle by a predetermined injection depth, which allows for smooth insertion of the needle into the patient's skin.
[0019] The assembly may further include a cap configured to cover the distal opening of the housing and including a grabber for removing a needle shield of the medication container, the grabber configured to be disposed at least partially radially between the distal extension and the needle. The grabber may include a radially outer surface oriented toward the distal extension. The grabber may include a radially inner surface oriented toward the needle shield and / or the needle. This may allow for smooth operation of the injection device.
[0020] Additionally, the coupling element may include a proximal extension configured to extend along the drug container body of the drug container. The proximal extension may be configured to closely radially surround the drug container body shape. The proximal extension may form a mounting sleeve for the drug container body. This may allow for a secure retention of the drug container.
[0021] According to further embodiments, the needle cover is configured to interact with a drive mechanism of the injection device to activate and / or enable ejection of the medicinal product upon movement of the needle cover from a first position to a second position relative to the housing, e.g. when the needle cover reaches the second position. Activation of ejection of the medicinal product may result in immediate ejection of the medicinal product upon movement of the needle cover. Enabling ejection of the medicinal product may release a locking mechanism preventing the ejection, while the actual activation may be triggered by a trigger element, e.g. an activation button, operated by the patient or user separately from the needle cover. This may allow for easy and / or safe operation of the injection device.
[0022] Preferably, the third support surface may be configured to contact the patient's skin before the needle cover interacts with the drive mechanism to activate and / or enable expulsion of the medicinal product. This may allow for easier and / or safer operation of the injection device. The transmission of impacts of the drive mechanism onto the patient's skin may thereby be attenuated.
[0023] The medication container may be pre-filled with medication.
[0024] The terms "drug" or "medication" are used synonymously herein to refer to a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharma- ceutically acceptable salts or solvates thereof, and optionally a pharma- ceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in the broadest sense, is a chemical structure that exerts a biological effect on humans or animals. In pharmacology, drugs or medicines are used to treat, cure, prevent, or diagnose disease, or otherwise improve physical or mental health. Drugs or medicines may be used for a limited duration or periodically for chronic diseases.
[0025] As described below, a drug or pharmaceutical product may include at least one API or a combination thereof in various types of formulations for the treatment of one or more diseases. Examples of APIs may include small molecules with molecular weights of 500 Da or less, polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments and enzymes), carbohydrates and polysaccharides, as well as nucleic acids, double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids or liposomes. Mixtures of one or more drugs are also contemplated.
[0026] The drug or pharmaceutical agent may be included in a primary package or "drug container" adapted for use with the drug delivery device. The drug container may be, for example, a cartridge, syringe, reservoir, or other solid or flexible container configured to provide a chamber suitable for storage (e.g., short-term or long-term storage) of one or more drugs. For example, in some cases, the chamber may be designed to store the drug for at least one day (e.g., from one day to at least 30 days). In some cases, the chamber may be designed to store the drug for about one month to about two years. Storage may be at room temperature (e.g., about 20° C.) or at refrigerated temperatures (e.g., from about −4° C. to about 4° C.). In some cases, the drug container may be or include a dual-chamber cartridge configured to separately store two or more components of a pharmaceutical formulation to be administered (e.g., an API and a diluent, or two different drugs), one in each chamber. In such cases, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and / or during administration to the human or animal body. For example, the two chambers may be configured to be in fluid communication with one another (e.g., via a conduit between the two chambers) and to allow mixing of the two components by a user prior to administration, if desired. Alternatively or additionally, the two chambers may be configured to allow mixing upon administration of the components to the human or animal body.
[0027] The drugs or pharmaceuticals contained in the drug delivery devices described herein can be used for the treatment and / or prevention of many different types of medical disorders. Examples of disorders include, for example, diabetes or complications associated with diabetes, such as diabetic retinopathy, thromboembolic disorders, such as deep vein thromboembolism or pulmonary thromboembolism. Further examples of disorders are acute coronary syndromes (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those listed in handbooks such as the Rote Liste 2014, for example, but not limited to, main groups 12 (antidiabetic drugs) or 86 (oncology drugs), and the Merck Index, 15th edition.
[0028] Examples of APIs for the treatment and / or prevention of type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin, e.g., human insulin, or a human insulin analog or derivative, glucagon-like peptide (GLP-1), a GLP-1 analog or GLP-1 receptor agonist, or an analog or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharma-ceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analog" and "derivative" refer to a polypeptide having a molecular structure that is formally derivable from the structure of a naturally occurring peptide, e.g., the structure of human insulin, by deletion and / or replacement of at least one amino acid residue present in the naturally occurring peptide and / or by addition of at least one amino acid residue. The added and / or replaced amino acid residues can be either codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogs are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide having a molecular structure formally derivable from the structure of a naturally occurring peptide, such as the molecular structure of human insulin with one or more organic substituents (e.g., fatty acids) attached to one or more of the amino acids. Optionally, one or more amino acids present in the naturally occurring peptide are deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable ones, are added to the naturally occurring peptide.
[0029] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline in position B28 can be replaced by Asp, Lys, Leu, Val or Ala and in position B29 Lys can be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
[0030] Examples of insulin derivatives are e.g. B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl-LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin. B29-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
[0031] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are e.g. lixisenatide (Lyxumia®), exenatide (exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide produced by the salivary glands of the flatfish), liraglutide (Victoza®), semaglutide, taspoglutide, albiglutide (Syncria®), dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, langrenatide / HM-11260C (efpegrenatide), HM-15211, CM-3, GLP-1 Erigen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexene, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, These include ZP-3022, ZP-DI-70, TT-401 (pegapamoditide), BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, tirzepatide (LY3298176), bamadutide (SAR425899) exenatide-XTEN and glucagon-Xten.
[0032] An example of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-lowering antisense therapeutic for the treatment of familial hypercholesterolemia, or RG012 for the treatment of Alport Syndrome.
[0033] Examples of DPP4 inhibitors include linagliptin, vildagliptin, sitagliptin, denagliptin, saxagliptin, and berberine.
[0034] Examples of hormones include pituitary or hypothalamic hormones or regulatory active peptides such as gonadotropins (follitropin, lutropin, chorion gonadotropin, menotropin), somatropin (somatropin), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin and goserelin, and their antagonists.
[0035] Examples of polysaccharides include glycosaminoglycans, hyaluronic acid, heparin, low molecular weight heparin, very low molecular weight heparin or derivatives thereof, or sulfated forms of the above polysaccharides, such as polysulfated forms, and / or pharmaceutically acceptable salts thereof.An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium.An example of a hyaluronic acid derivative is Hylan GF 20 (Synvisc®), sodium hyaluronate.
[0036] The term "antibody" as used herein refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of an immunoglobulin molecule include F(ab) and F(ab')2 fragments that retain the ability to bind to an antigen. An antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., murine) antibody, or a single chain antibody. In some embodiments, an antibody has effector functions and can fix complement. In some embodiments, an antibody has reduced or no binding ability to Fc receptors. For example, an antibody can be an isotype or subtype, an antibody fragment, or a mutant that does not support binding to Fc receptors, e.g., with mutations or deletions of the Fc receptor binding region. The term antibody also includes antigen-binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTIs) and / or dual variable region antibody-like binding proteins with crossover binding region orientation (CODV).
[0037] The term "fragment" or "antibody fragment" refers to a polypeptide (e.g., antibody heavy and / or light chain polypeptide) derived from an antibody polypeptide molecule that does not include the full-length antibody polypeptide but comprises at least a portion of the full-length antibody polypeptide that is still capable of binding to an antigen. An antibody fragment may include truncated portions of a full-length antibody polypeptide, but the term is not limited to such truncated fragments. Antibody fragments useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments, such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments, such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIPs), binding domain immunoglobulin fusion proteins, camelized antibodies and VHH-containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
[0038] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences within the variable regions of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences within the variable regions of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the proper arrangement of the CDR sequences to allow antigen binding. Although the framework region itself typically does not directly participate in antigen binding, as is known in the art, certain residues within the framework region of a particular antibody may be directly involved in antigen binding or may affect the ability of one or more amino acids within the CDR to interact with the antigen.
[0039] Examples of antibodies are anti-PCSK-9 mAb (e.g., alirocumab), anti-IL-6 mAb (e.g., sarilumab), and anti-IL-4 mAb (e.g., dupilumab).
[0040] Pharmaceutically acceptable salts of any of the APIs described herein are contemplated for use in the drug or pharmaceutical agent in the drug delivery device. Pharmaceutically acceptable salts include, for example, acid addition salts and base salts.
[0041] It will be understood by those skilled in the art that modifications (addition and / or deletions) may be made to the various components of the APIs, formulations, devices, methods, systems and embodiments described herein without departing from the full scope and spirit of the invention, and that the invention encompasses such modifications and all equivalents thereof.
[0042] Exemplary drug delivery devices may include needle-based injection systems as described in Table 1 of Section 5.2 of ISO 11608-1:2014(E). As described in ISO 11608-1:2014(E), needle-based injection systems may be broadly categorized into multi-dose container systems and single-dose (with partial or complete evacuation) container systems. The container may be an exchangeable container or an integrated non-exchangeable container.
[0043] As further described in ISO 11608-1:2014(E), a multi-dose container system may include a needle-based injection device with an exchangeable container. In such a system, each container holds multiple doses and the size may be fixed or variable (pre-set by the user). Another multi-dose container system may include a needle-based injection device with an integrated non-exchangeable container. In such a system, each container holds multiple doses and the size may be fixed or variable (pre-set by the user).
[0044] As further described in ISO 11608-1:2014(E), the single-dose container system may include a needle-based injection device with a replaceable container. In one example of such a system, each container holds a single dose, which expels the entire deliverable volume (full expulsion). In a further example, each container holds a single dose, which expels a portion of the deliverable volume (partial expulsion). As also described in ISO 11608-1:2014(E), the single-dose container system may include a needle-based injection device with an integrated non-replaceable container. In one example of such a system, each container holds a single dose, which expels the entire deliverable volume (full expulsion). In a further example, each container holds a single dose, which expels a portion of the deliverable volume (partial expulsion).
[0045] Furthermore, an injection device, for example an automatic injection device, is proposed, comprising the assembly described above and a drive mechanism configured to expel a medicine from a medicine container when activated. The drive mechanism may comprise an energy store. The energy store may be pre-charged, for example during assembly of the injection device. The energy store may be, for example, a mechanical energy store, for example in the form of a compressed spring. Alternatively, the energy store may be electrical or pneumatic, for example compressed gas. Compared to other injection devices, the automatic injection device may be configured to automatically perform the ejection of the medicine, for example by the drive mechanism, after the ejection of the medicine has been initiated without requiring any further action of the user of the injection device. In an alternative embodiment, the ejection of the medicine may require a certain action of the user, for example the application of a drive force, even after the ejection of the medicine has been initiated. [Brief description of the drawings]
[0046] [Figure 1] FIG. 2 is a perspective and partially transparent view of an injection device including an assembly in a schematic diagram in a second operational state. [Figures 2a-2d] 1A-1C are cross-sectional views of an assembly in first, second, third and fourth operating states. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] In the figures, identical elements, identically functioning elements, or elements of the same type may be labeled with the same reference numbers.
[0048] In this specification, "distal" is used to designate a direction, end, or surface that is or will be located facing or facing towards the dispensing end of the drug delivery device or a component thereof and / or that faces away from, faces away from, or faces away from the proximal end. On the other hand, "proximal" is used to designate a direction, end, or surface that is or will be located facing away from the dispensing end and / or the distal end of the drug delivery device or a component thereof. The distal end may be the end closest to the dispensing end and / or the end furthest from the proximal end, and the proximal end may be the end furthest from the dispensing end. The proximal face may face away from the distal end and / or towards the proximal end. The distal face may face towards the distal end and / or away from the proximal end. The dispensing end may be, for example, the needle end where the needle unit is present or will be attached to the device.
[0049] The distal direction may be the direction in which the tip of the needle is oriented. The proximal direction may be the direction opposite to the distal direction. The distal and proximal directions may be aligned along a major axis. The major axis may be collinear with the needle or run through the needle. Any or all moving components of the injection device may be configured to move along and / or rotate about the major axis. The radial direction may be any direction perpendicular to the major axis. The major axis may be the axis along which most of the components of the injection device are located and / or oriented. The major axis may be the axis of lowest moment of inertia of the injection device, or at least close to such an axis.
[0050] FIG. 1 shows an injection device 10. The injection device 10 is an automatic injection device. The injection device 10 is a pen-type device. The injection device includes an assembly 20 (compare also FIGS. 2a-d) and a drive mechanism 12. The drive mechanism 12 may be part of the assembly. Details of the drive mechanism 12 may be found in WO 2015 / 004052 A, the disclosure of which is incorporated herein. The drive mechanism may be the same or similar to that disclosed in WO 2015 / 004052 A. An assembly 20 for the injection device 10 is configured to include a drug container 30. The assembly 20 includes the drug container 30. The drug container 30 includes a drug container body 32 and a needle 34 protruding from the drug container body 32. The needle 34 is fluidly connected to the interior of the drug container body 32. The drug container 30 is pre-filled with a drug. The drive mechanism 12 is configured to expel a drug from the drug container 30 when actuated. The drive mechanism 12 includes an energy storage (not shown) and a plunger 14, where the energy storage is configured to drive the plunger, for example, in a distal direction 16 and / or into the drug container 30. The plunger 14 is configured to interact with the drug container 30 to expel the drug from the drug container 30. The energy storage can be, for example, a compression spring disposed within the plunger 14.
[0051] The assembly 20 further includes a housing 22. The housing includes a first support surface 23 configured to support the medication container 30 in the distal direction 16.
[0052] The assembly 20 further includes a needle cover 26 including a second support surface 27 configured to protrude further from the housing 22 than the needle 34 of the drug container 30 in at least a first state, the needle cover 26 being disposed within the housing 22 to move telescopically within the housing 22 when a force is applied in a proximal direction, the needle cover 26 including an opening through which the needle 34 passes when the needle cover 26 is moved to a second position within the housing 22. The needle cover 26 radially covers at least a portion of the needle 34 protruding from the housing 22 in the first position of the needle cover 26, e.g., in the first and second operating states (FIGS. 2a and 2b). The needle cover 26 includes a cylindrical shape at least in the area where the needle 34 protrudes from the housing 22. The second support surface 27 is disposed on a distal end of the needle cover 26. The needle cover 26 may include a section formed on the distal end of the needle cover 26 and extending radially inward.
[0053] The needle cover 26 is arranged within the housing 22 to move elastically within the housing 22 when a force is applied in a proximal direction, for example by pressing the second support surface 27 against the patient's skin 50. The needle cover 26 includes a distal opening for the needle 34 and coupling element 36 to pass therethrough when the needle cover 26 is moved to or beyond the second position within the housing 22, for example in a third operating state (compare FIG. 2c).
[0054] The assembly 20 further includes a coupling element 36 configured to move the drug container 30 in a proximal direction parallel to the needle cover 26 when the needle cover 26 is moved in a proximal direction beyond the second position. The coupling element 36 is configured to urge the drug container 20 in a proximal direction such that the drug container body 32 is at a proximal distance relative to the first support surface 23 during use of the injection device 10, for example when the needle cover 26 is moved in a proximal direction beyond the second position.
[0055] The coupling element 36 is disposed on the first support surface. The coupling element 36 is configured to be disposed between the first support surface 23 and the medication container 32, e.g., along the distal direction 16. The coupling element 36 provides a third support surface 37 disposed on a distal end of the distal extension 39. The third support surface 37 is configured to be inserted into the opening of the needle cover 26 when the needle cover is moved to the second position, and to contact the patient's skin 50 during use of the injection device 10 when the needle cover reaches the second position. The coupling element 36 thereby prevents the needle 34 from being inserted into the patient's body 52 beyond a predetermined injection depth.
[0056] The coupling element 36 includes a distal extension 39 configured to extend along the needle 34 of the drug container 30. The distal extension 39 extends from a support surface configured to provide support for the drug container body 32 in the distal direction 16. The distal extension 39 extends parallel to the needle 34.
[0057] During use of the injection device 10 , the coupling element 36 is configured to axially displace the medication container 30 in a proximal direction (opposite the distal direction 16 ) from the first support surface 23 .
[0058] The distal extension 39 is formed as a hollow cylinder configured to surround at least a portion of the needle 34. The needle 34 is positioned along the center of the hollow cylinder. The needle 34 is positioned such that for any point along the needle, the distance in any radial direction from the needle 34 to the distal extension 39 is constant.
[0059] Distal extension 39 is disposed along all portions of needle 34 that remain outside of the patient's body 52 during use of the injection device.
[0060] The third support surface 37 is axially offset from the needle tip 35 of the needle 34 in the distal direction 16 a predetermined injection depth.
[0061] The coupling element 36 is made of an essentially rigid material. The coupling element 36, for example at least the distal extension 39, is made of a polymer and / or metal, for example a medical grade polymer such as PC / ACB, nylon, glass-filled nylon, and / or POM, or a metal such as stainless steel. The third support surface may be formed as a flat surface, for example compared to the edge, preferably the entire support surface is arranged in a plane. Alternatively, a conical shape of the support surface is possible, for example to fit the patient's skin in a specific way.
[0062] Medication container 30 further includes a needle shield 38 configured to cover at least needle tip 35 and a portion of needle 34. The portion of needle shield 38 is disposed between needle 34 and coupling element 36 when viewed radially from needle 34.
[0063] The needle shield 38 is configured to be removed prior to use of the injection device 10 .
[0064] The assembly 20 further includes a cap 24 covering a distal opening of the housing 22. The cap 24 is releasably coupled to the housing 22. The cap 24 includes a grabber 25 for removing a needle shield 38 of the medication container 30. The grabber 25 is mechanically locked to the needle shield 38 such that the needle shield 38 is removed from the needle 34 when the cap 24 is removed from the housing 22. The grabber 25 is configured to be partially radially disposed between the distal extension 39 and the needle 34.
[0065] In a first operating state (compare FIG. 2a), the cap 24 may still be attached to the housing 22. In a second operating state, the cap 24 and the needle shield 38 have been removed and the injection device 10 is ready for use (compare FIG. 2b).
[0066] The coupling element 36 further includes a proximal extension configured to extend along the drug container body 32 of the drug container 30. The proximal extension includes a cylindrical shape. The distal extension 39 includes a first section and a second section. The first section and the second section may each include a hollow cylindrical shape. The first section has a smaller diameter than the second section while having the same or similar wall thickness. The third support surface 37 is disposed on a distal end of the second section. The distal extension 39 may include a ring-shaped element disposed between the distal end of the first section and the proximal end of the second section to bridge the gap between the two sections. The coupling element 36 includes the distal extension 39, e.g., a second ring-shaped portion disposed between the first section and the proximal extension. The first section includes a smaller diameter than the proximal extension. The first section and the proximal extension include the same or similar wall thickness. The second ring-shaped portion provides a distal support surface that interacts with the first support surface 23 in the distal direction 16. The second ring-shaped portion provides a proximal support surface for supporting the medication container 30 in the distal direction 16.
[0067] The needle cover 26 is configured to interact with the drive mechanism 12 of the injection device 10 to activate and / or enable the expulsion of the medication. When the needle cover 26 reaches / arrives in the third position, the needle cover 26 loses engagement with the plunger 14. In one embodiment, the energy store may be configured to drive the plunger 14 in a distal direction and interact with the medication container 20 to release the medication as soon as the needle cover 26 loses engagement with the plunger 14. In another embodiment, an additional user action, e.g., a button press, may be required to release the stored energy and move the plunger 14 after the needle cover 26 loses engagement with the plunger 14.
[0068] The third support surface 35 is configured to contact the patient's skin 50 before the needle cover 26 interacts with the drive mechanism 12 to activate and / or enable the expulsion of the medication.
[0069] In a fourth operational state (FIG. 2d), the proximal support surface of the needle cover 26 may contact the distal support surface of the housing 22 such that further movement of the needle cover 26 into the housing 22 is prevented. The fourth and third operational states may be the same operational state. In the fourth operational state, the medication container 20 is further proximal to the first support surface 23 than in the third operational state.
[0070] The needle cover 26 covers at least a portion of the distal extension 39 protruding from the housing 22 in at least the first state, e.g., also in the second state, and the opening is configured to allow the distal extension 39 to pass when the needle cover 26 is moved sufficiently deep within the housing 22.
[0071] The assembly 20 and / or the injection device 10 may be provided by using a further assembly, the further assembly including a drug container 30 including a drug container body 32 and a needle 34 protruding from and fluidly connected to the interior of the drug container body 32, the further assembly also including a housing 22 providing a first support surface 23 for supporting the drug container 30 in a distal direction, the needle 34 configured to be inserted further into the patient's body 52 to a predetermined injection depth during use of the injection device 10, and a coupling element 36 disposed between the drug container 30 and the first support surface 23 providing a third support surface 37 configured to contact the patient's skin 50, for example on a distal extension 39, during use of the injection device 10, thereby preventing the needle 34 from being inserted into the patient's body 52 beyond a predetermined injection depth that is less than the further predetermined injection depth. The further assembly may include the housing 22, the needle cover 26, the cap 24, and / or the drive mechanism 12.
[0072] During manufacture of the injection device, the drug container 30 may be inserted into the coupling element 36 either before or after the coupling element 36 is disposed within the housing 22 . [Explanation of symbols]
[0073] 10 Injection device 12 Drive mechanism 14 Plunger 16 Distal 20 Assembly 22 Housing 23 Support surface 24 Cap 25 Graba 26 Needle cover 27 Support surface 30 Pharmaceutical containers 32 Pharmaceutical container body 34 needles 35 Needle Tip 36 Bonding Elements 37 Support surface 38 Needle Shield 39 Distal extension
Claims
1. An assembly for an injection device (10), e.g. an autoinjector, comprising: a housing (22) including a first support surface (23) configured to support a medicament container (30) in a distal direction (16); a needle cover (26) including a second support surface (27) configured to protrude from the housing (22) further than the needle (34) of the pharmaceutical container (30) at least in a first state and in a first position, the needle cover (26) being arranged within the housing (22) for telescopic movement within the housing (22) upon application of a force in a proximal direction, the needle cover (26) including an opening through which the needle (34) passes when the needle cover (26) is moved to a second position within the housing (22); a coupling element (36) configured to move the medicament container (30) in the proximal direction parallel to the needle cover (26) when the needle cover (26) is moved in the proximal direction beyond the second position; An assembly comprising:
2. 2. The assembly of claim 1, wherein the coupling element (36) is disposed on the first support surface (23) and configured to be disposed between the first support surface (23) and the drug container (30), the coupling element (36) including a distal extension (39) configured to extend along a needle (34) of the drug container.
3. 3. The assembly of claim 1 or 2, wherein the coupling element (36) includes a third support surface (37) disposed on a distal end of the coupling element (36).
4. 4. The assembly of claim 3, wherein the third support surface (37) is configured to be inserted into the opening of the needle cover (26) when the needle cover (26) is moved to the second position and to contact the patient's skin (50) when the needle cover (26) reaches the second position.
5. The assembly according to any one of claims 2 to 4, wherein the distal extension (39) is formed as a hollow cylinder configured to surround at least a portion of the needle (34).
6. 6. The assembly of claim 3, wherein the third support surface (37) is configured to be axially offset from the needle tip (35) of the needle (34) by a predetermined injection depth.
7. 7. The assembly of claim 2, further comprising a cap (24) configured to cover a distal opening of the housing (22) and including a grabber (25) for removing a needle shield (38) of the pharmaceutical container (30), the grabber (25) configured to be disposed at least partially radially between the distal extension (39) and the needle (34).
8. The assembly of any one of claims 1 to 7, wherein the coupling element (36) includes a proximal extension configured to extend along a drug container body (32) of the drug container (30).
9. The assembly of any one of claims 1 to 8, wherein the needle cover (26) is configured to interact with a drive mechanism (12) of the injection device to activate and / or enable ejection of a medicinal product, for example when the needle cover (26) moves beyond the second position to reach a third position.
10. 10. The assembly of claim 3 or 9, wherein the third support surface (37) is configured to contact the patient's skin (50) before the needle cover (26) interacts with the drive mechanism (12) to activate and / or enable expulsion of the medicinal product.
11. The assembly of any one of claims 1 to 10, further comprising the drug container (30), the drug container (30) being pre-filled with a drug.
12. Assembly according to any one of the preceding claims, wherein the coupling element (36) is rigid and / or non-deformable, for example when subjected to an axial force.
13. An injection device, such as an autoinjector, comprising an assembly (20) according to any one of the preceding claims.
14. An assembly for an injection device (10), e.g. an autoinjector, comprising: a housing (22) including a first support surface (23) configured to support a medicament container (30) in a distal direction (16); a needle cover (26) including a second support surface (27) configured to protrude from the housing (22) further than the needle (34) of the pharmaceutical container (30) at least in a first state and in a first position, the needle cover (26) being arranged within the housing (22) for telescopic movement within the housing (22) upon application of a force in a proximal direction, the needle cover (26) including an opening through which the needle (34) passes when the needle cover (26) is moved to a second position within the housing (22); a coupling element (36) configured to move the medicament container (30) in the proximal direction parallel to the needle cover (26) when the needle cover (26) is moved in the proximal direction beyond the second position; Equipped with The assembly, wherein the coupling element (36) includes a third support surface (37) disposed on a distal end of the coupling element (36).
